ADAMTS13
A disintegrin and metalloproteinase with thrombospondin motifs 13
Also known as: ATS13_HUMAN, C9orf8, DKFZp434C2322, FLJ42993, MGC118899, MGC118900, TTP, vWF-CP, VWFCP
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q76LX8
- Gene
- ADAMTS13
- Ensembl
- ENSG00000160323
- Chromosome
- 9
- Canonical length
- 1427 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Nucleoplasm,Vesicles
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes a member of a family of proteins containing several distinct regions, including a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. The enzyme encoded by this gene specifically cleaves von Willebrand Factor (vWF). Defects in this gene are associated with thrombotic thrombocytopenic purpura. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
Canonical amino-acid sequenceUniProt
1427 residues, UniProt reviewed canonical sequence.
>Q76LX8|ADAMTS13
1 MHQRHPRARC PPLCVAGILA CGFLLGCWGP SHFQQSCLQA LEPQAVSSYL SPGAPLKGRP
61 PSPGFQRQRQ RQRRAAGGIL HLELLVAVGP DVFQAHQEDT ERYVLTNLNI GAELLRDPSL
121 GAQFRVHLVK MVILTEPEGA PNITANLTSS LLSVCGWSQT INPEDDTDPG HADLVLYITR
181 FDLELPDGNR QVRGVTQLGG ACSPTWSCLI TEDTGFDLGV TIAHEIGHSF GLEHDGAPGS
241 GCGPSGHVMA SDGAAPRAGL AWSPCSRRQL LSLLSAGRAR CVWDPPRPQP GSAGHPPDAQ
301 PGLYYSANEQ CRVAFGPKAV ACTFAREHLD MCQALSCHTD PLDQSSCSRL LVPLLDGTEC
361 GVEKWCSKGR CRSLVELTPI AAVHGRWSSW GPRSPCSRSC GGGVVTRRRQ CNNPRPAFGG
421 RACVGADLQA EMCNTQACEK TQLEFMSQQC ARTDGQPLRS SPGGASFYHW GAAVPHSQGD
481 ALCRHMCRAI GESFIMKRGD SFLDGTRCMP SGPREDGTLS LCVSGSCRTF GCDGRMDSQQ
541 VWDRCQVCGG DNSTCSPRKG SFTAGRAREY VTFLTVTPNL TSVYIANHRP LFTHLAVRIG
601 GRYVVAGKMS ISPNTTYPSL LEDGRVEYRV ALTEDRLPRL EEIRIWGPLQ EDADIQVYRR
661 YGEEYGNLTR PDITFTYFQP KPRQAWVWAA VRGPCSVSCG AGLRWVNYSC LDQARKELVE
721 TVQCQGSQQP PAWPEACVLE PCPPYWAVGD FGPCSASCGG GLRERPVRCV EAQGSLLKTL
781 PPARCRAGAQ QPAVALETCN PQPCPARWEV SEPSSCTSAG GAGLALENET CVPGADGLEA
841 PVTEGPGSVD EKLPAPEPCV GMSCPPGWGH LDATSAGEKA PSPWGSIRTG AQAAHVWTPA
901 AGSCSVSCGR GLMELRFLCM DSALRVPVQE ELCGLASKPG SRREVCQAVP CPARWQYKLA
961 ACSVSCGRGV VRRILYCARA HGEDDGEEIL LDTQCQGLPR PEPQEACSLE PCPPRWKVMS
1021 LGPCSASCGL GTARRSVACV QLDQGQDVEV DEAACAALVR PEASVPCLIA DCTYRWHVGT
1081 WMECSVSCGD GIQRRRDTCL GPQAQAPVPA DFCQHLPKPV TVRGCWAGPC VGQGTPSLVP
1141 HEEAAAPGRT TATPAGASLE WSQARGLLFS PAPQPRRLLP GPQENSVQSS ACGRQHLEPT
1201 GTIDMRGPGQ ADCAVAIGRP LGEVVTLRVL ESSLNCSAGD MLLLWGRLTW RKMCRKLLDM
1261 TFSSKTNTLV VRQRCGRPGG GVLLRYGSQL APETFYRECD MQLFGPWGEI VSPSLSPATS
1321 NAGGCRLFIN VAPHARIAIH ALATNMGAGT EGANASYILI RDTHSLRTTA FHGQQVLYWE
1381 SESSQAEMEF SEGFLKAQAS LRGQYWTLQS WVPEMQDPQS WKGKEGTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ADAMTS13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.38
- Highest tissue expression
- 63 nTPM
Expression across tissuesHPA
Tissue
- liver: 63 nTPM
- cerebellum: 18 nTPM
- cerebral cortex: 14 nTPM
- testis: 13 nTPM
- pituitary gland: 12 nTPM
- hippocampal formation: 11 nTPM
Single-cell type
- astrocytes: 20 nCPM
- ependymal cells: 14 nCPM
- brain inhibitory neurons: 14 nCPM
- brain excitatory neurons: 12 nCPM
- bergmann glia: 12 nCPM
- proximal tubule cells: 11 nCPM
Immune cell
- basophil: 0.6 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 7.7 nTPM
- cerebellum: 6.4 nTPM
- thalamus: 5.6 nTPM
- basal ganglia: 5.4 nTPM
- medulla oblongata: 5.3 nTPM
- pons: 5.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ADAMTS13.
Disease | AllUniProt
Conditions ADAMTS13 is implicated in, by any mechanism.
- Thrombotic thrombocytopenic purpura, hereditary (TTP) MIM:274150
Disease | GeneticClinVar
126 pathogenic / likely-pathogenic of 1,176 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Upshaw-Schulman syndrome
- Thrombotic thrombocytopenic purpura
- ADAMTS13-related disorder
- Abnormal bleeding
- Thrombocytopenia
Disease | ImmuneIEDB
Conditions an epitope on ADAMTS13 was assayed in.
- thrombotic thrombocytopenic purpura T cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against ADAMTS13 are reported. Each links to that disease's full target list.
- Purpura, Thrombotic Thrombocytopenic 249
- Purpura, Thrombocytopenic, Idiopathic 27
- Thrombosis 18
- Lupus Erythematosus, Systemic 15
- Antiphospholipid Syndrome 7
- COVID-19 5
- HIV Infections 5
- Thrombocytopenia 5
- Acute Kidney Injury 4
Showing 9 of 16 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for ADAMTS13 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
331 publications
- Thrombotic thrombocytopenic purpura.
2017 · Blood · RCR 25.1 · 551 citations - ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.
2020 · J Thromb Haemost · RCR 20.9 · 311 citations - Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management.
2021 · J Clin Med · RCR 15.9 · 181 citations - Thrombotic thrombocytopenic purpura.
2017 · Nat Rev Dis Primers · RCR 12.9 · 288 citations - Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
2016 · Lancet Haematol · RCR 10.9 · 247 citations
Show 20 more of 331 total
- ADAMTS proteins in human disorders.
2018 · Matrix Biol · RCR 9.8 · 231 citations - Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.
2006 · Blood · RCR 8.4 · 303 citations - ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
2015 · Annu Rev Med · RCR 7.4 · 196 citations - Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
2007 · Br J Haematol · RCR 6.7 · 220 citations - Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
2005 · Blood · RCR 6.6 · 218 citations - ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
2008 · Haematologica · RCR 6.4 · 223 citations - ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.
2005 · Blood · RCR 6.3 · 224 citations - Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.
2007 · Blood · RCR 6.1 · 217 citations - Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023.
2023 · Int J Hematol · RCR 5 · 31 citations - Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism.
2025 · Haematologica · RCR 5 · 13 citations - Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.
2017 · Blood · RCR 5 · 102 citations - ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura.
2023 · Res Pract Thromb Haemost · RCR 4.9 · 28 citations - Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.
2017 · J Thromb Haemost · RCR 4.7 · 109 citations - Thrombotic microangiopathy and associated renal disorders.
2012 · Nephrol Dial Transplant · RCR 4.7 · 131 citations - How I treat refractory thrombotic thrombocytopenic purpura.
2015 · Blood · RCR 4.7 · 126 citations - Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.
2020 · Blood · RCR 4.6 · 76 citations - Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.
2004 · Blood · RCR 4.4 · 176 citations - Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
2015 · EBioMedicine · RCR 4.3 · 111 citations - Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008.
2010 · Intern Med · RCR 4.2 · 128 citations - von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.
2003 · Blood · RCR 4.1 · 157 citations
Reference: T cellIEDB
1 publication
- The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope.
2017 · Haematologica · RCR 0.3 · 10 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.68
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.56
- DepMap mean gene effect
- 0.1
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- blood coagulation
- cell-matrix adhesion
- cellular response to interleukin-4
- cellular response to lipopolysaccharide
- cellular response to tumor necrosis factor
- cellular response to type II interferon
- extracellular matrix organization
- glycoprotein metabolic process
- integrin-mediated signaling pathway
- peptide catabolic process
- platelet activation
- protein catabolic process
- protein processing
- proteolysis
- response to amine
- response to potassium ion
- response to toxic substance
Molecular functions
- calcium ion binding
- integrin binding
- metalloendopeptidase activity
- metallopeptidase activity
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Thrombospondin type-1 (TSP1) repeat
- Peptidase M12B, ADAM/reprolysin
- ADAM, cysteine-rich domain
- ADAMTS/ADAMTS-like, Spacer 1
- ADAMTS/ADAMTS-like
- Metallopeptidase, catalytic domain superfamily
- Spermadhesin, CUB domain superfamily
- Thrombospondin type-1 repeat superfamily
- ADAMTS, cysteine-rich domain 2
- ADAMTS/ADAMTS-like, cysteine-rich domain 3
- ADAMTS and ADAMTS-like
- Thrombospondin type 1 domain
- Reprolysin (M12B) family zinc metalloprotease
- ADAM-TS Spacer 1
- ADAMTS cysteine-rich domain 2
- Thrombospondin type 1 domain
- ADAMTS cysteine-rich domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ADAMTS13 as an antibody target. Whether an autoantibody or antibody against ADAMTS13 could matter depends on whether native ADAMTS13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ADAMTS13 is annotated as secreted, so native ADAMTS13 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label ADAMTS13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...